All In Biotech

Drug Trial Radar · NCT02943655

Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause

Combined Oral Contraceptives, Progestogens, and Non-steroidal Anti-inflammatory Drugs for Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause

Last checked: Nov 20, 2026Latest source record: Jun 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Nov 1, 2017

Primary completion

Oct 10, 2020

Study completion Feb 10, 2021

Sponsor

Lead sponsor
Assiut UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 25 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Abnormal uterine bleeding encompasses abnormalities in the regularity, duration of flow, frequency, and/or blood flow volume relative to normal menstruation. Of these menstrual abnormalities, heavy menstrual bleeding (HMB), defined objectively as a blood loss of 80 ml or more per menstrual cycle , which is unrelated to pregnancy or known pelvic or systemic disease.

Conditions

  • Improve Quality of Life
  • Heavy Menstrual Bleeding

Interventions

  • combined contraceptive pills (microcept)Drug

    oral combined contraceptive once daily

  • medroxyprogesterone acetate (progest)Drug

    oral 5 mg medroxyprogesterone acetate daily

  • mefenamic acid (ponstan forte)Drug

    oral 500 mg mefenamic acid three times per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the amount of menstrual blood lossTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ahmed Abbas

    Assiut, Cairo Governorate, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.